Boehringer Ingelheim’s blood-thinning drug Pradaxa (dabigatran etexilate) is a $1 billion industry unto itself. Developed to usurp Coumadin's (Warfarin) dominance over the blood thinner market, Pradaxa initially showed some promise…
Jeff LoweSeptember 20, 2012